已发表论文

c-Met:一个有前途的膀胱癌治疗靶点

 

Authors Feng Y, Yang Z, Xu X

Received 6 April 2022

Accepted for publication 20 July 2022

Published 8 August 2022 Volume 2022:14 Pages 2379—2388

DOI https://doi.org/10.2147/CMAR.S369175

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Kattesh V Katti

Abstract: Mesenchymal-epithelial transition factor (c-Met) belongs to the tyrosine kinase receptor family and is overexpressed in various human cancers. Its ligand is hepatocyte growth factor (HGF), and the HGF/c-Met signaling pathway is involved in a wide range of cellular processes, including cell proliferation, migration, and metastasis. Emerging studies have indicated that c-Met expression is strongly associated with bladder cancer (BCa) development and prognosis. Therefore, c-Met is a potential therapeutic target for BCa treatment. Recently, the aberrant expression of noncoding RNAs was found to play a significant role in tumour progression. There is a close connection between c-Met and noncoding RNA. Herein, we summarized the biological function and prognostic value of c-Met in BCa, as well as its potential role as a drug target. The relation of c-Met and ncRNA was also described in the paper.
Keywords: c-Met, HGF, noncoding RNA, bladder cancer, review